文献速递介入腹部CTMRDSA

放射性肝段切除治疗大于3 cm肝寡转移

Radiation segmentectomy for treatment of hepatic oligometastases greater than 3 cm.
PubMed 文献 · Eur J Radiol · 2026-01-05

本研究回顾性纳入2017年12月至2024年2月单中心14例大于3 cm肝继发肿瘤患者,采用钇-90玻璃微球行放射栓塞,段切除定义为靶剂量>200 Gy且不超过两个肝段。结果显示3个月严重不良反应少,初步提示该方法可行。

要点

  • 大于3 cm肝寡转移可考虑放射性肝段切除,靶剂量>200 Gy且局限于≤2个肝段
  • 本组疾病控制率为85.7%,中位无进展生存16.3个月,中位总生存24.3个月
  • 主要严重不良反应为1例3级血小板减少,未观察到其他≥3级不良事件

核心结论

  • 初步结果显示,放射性肝段切除用于大于3 cm的肝继发肿瘤是一种可行治疗选择,主要不良反应发生率低。

研究设计与样本

  • 单中心回顾性研究,纳入2017年12月至2024年2月14例因肝转移接受玻璃钇-90微球经动脉放射栓塞的患者
  • 纳入标准为继发性肝肿瘤直径大于3 cm,采用放射性肝段切除,定义为靶剂量超过200 Gy且治疗不超过两个肝段

关键影像表现/征象

  • 本组继发肝肿瘤平均直径为4.7±1.4 cm,57.1%(8/14)为单发肝病灶
  • 原发肿瘤类型包括结直肠癌5例、肾细胞癌2例、葡萄膜黑色素瘤2例、腺样囊性癌2例、胰腺腺癌1例、子宫内膜癌1例及扁桃体腺癌1例

诊断标准与关键数值

  • 放射性肝段切除定义为靶剂量>200 Gy且治疗范围不超过两个肝段
  • 本组平均肝段切除剂量为352.6±149.1 Gy
  • 影像缓解率为42.9%(6/14),疾病控制率为85.7%(12/14)
  • 1年和3年靶病灶缓解率分别为51.4%(95%CI:21.9-74.8%)和34.2%(95%CI:7.1-64.9%),中位无进展生存16.3个月(95%CI:5.4个月-未达到)
  • 1年和3年总生存率分别为80.8%(95%CI:42.4-94.9%)和40.4%(95%CI:9.8-70.2%),中位总生存24.3个月(95%CI:8.9-未达到)

临床应用与阅片要点

  • 对不适合经皮热消融或消融覆盖受限的3 cm以上肝寡转移,可评估采用放射性肝段切除作为局部根治性手段
  • 阅片随访时需重点关注治疗后靶病灶缓解、靶区外肝内进展及肝外进展,以判断疾病控制和无进展生存
  • 需注意血液学毒性,本组1例出现3级血小板减少并需暂停全身治疗,报告随访影像时应同时关注临床实验室指标

局限性

  • 该研究为单中心回顾性设计,样本量仅14例,肿瘤类型异质性较大
  • 原文仅报告初步结果,随访时间和事件数有限,生存及毒性数据仍需更大队列验证

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The effectiveness of percutaneous thermoablation as curative treatment of hepatic oligometastases greater than 3 cm can be limited by the ability to achieve adequate ablation coverage. Radiation segmentectomy (RS) using yttrium-90 (Y90) microspheres is an established treatment and potentially curative for hepatocellular carcinoma (HCC) up to 8 cm. This study evaluates the safety and effectiveness of RS for secondary liver tumors larger than 3 cm.

METHODS: A retrospective review at a single institution was performed from December 2017 to February 2024 to include patients treated with transarterial radioembolization (TARE) for liver metastases using glass Y90 microspheres. RS was defined as a target dose > 200 Gy to no more than two liver segments. The following outcomes were retrieved: overall survival (OS), radiologic response, progression-free survival (PFS), adverse events, and 3-month serum toxicity.

RESULTS: A total of 14 patients (mean age: 64.2 ± 18.5, M:F = 5:9) with secondary liver tumors (mean diameter: 4.7 ± 1.4 cm; single hepatic lesion: 57.1 %[8/14]), including 5 colorectal cancer (35.7 %), 2 renal cell carcinoma (14.3 %), 2 uveal melanoma (14.3 %), 2 adenoid cystic carcinoma (14.3 %), 1 pancreatic adenocarcinoma (7.1 %), 1 endometrial carcinoma (7.1 %), and 1 tonsillar adenocarcinoma (7.1 %). The mean segmentectomy dose was 352.6 ± 149.1 Gy. Response rate and disease control rate were 42.9 % (6/14) and 85.7 % (12/14), respectively. The 1-yr and 3-yr target tumor response rates were 51.4 % (95 %CI: 21.9-74.8 %) and 34.2 % (95 %CI: 7.1-64.9 %), respectively, with a median PFS of 16.3 months 95 %CI: 5.4 months-not reached). The 1-yr and 3-yr OS were 80.8 % (95 %CI: 42.4-94.9 %) and 40.4 % (95 %CI: 9.8-70.2 %), respectively, with a median OS of 24.3 months (95 %CI: 8.9-not reached). One patient developed grade 3 thrombocytopenia, requiring holding of systemic treatment (7.1 %). No additional grade 3 or above adverse events occurred.

CONCLUSION: Preliminary results suggest that RS is a feasible treatment option for secondary liver tumors > 3 cm with few major adverse events.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Yu, Ahmed, Badar, et al. Radiation segmentectomy for treatment of hepatic oligometastases greater than 3 cm. Eur J Radiol. 2026. PMID: 41576426. doi:10.1016/j.ejrad.2026.112657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。